This contract expires in 188 days (Jan 12, 2027).
BRISTOL-MYERS SQUIBB COMPANY - REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS
Key Details
Description
REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS
Context & Analysis
On Jan 13, 2026, Department of Veterans Affairs obligated $911,453.97 to BRISTOL-MYERS SQUIBB COMPANY for revlimid, pomalyst, camzyos specialty pharmaceuticals. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in LAWRENCEVILLE, NJ. The contract is scheduled through Jan 12, 2027 — approximately 6 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.